Barcelona Liver Bioservices will be present at the ILC-EASL 2019

Barcelona Liver Bioservices (BLB), CRO especially focused on the field of Hepatology, announced today its participation in the upcoming International Liver Congress (ILC) 2019 – the annual meeting of the European Association for the Study of the Liver (EASL) that will take place in Vienna in April 10-14th 2019.

BLB’s participation in the meeting will include scientific contribution and official representation. From the scientific point-of-view, BLB will present the results of two studies: The works entitled “A nutraceutical supplement rich in docosahexaenoic acid improves portal hypertension in a pre-clinical model of chronic liver disease” and “Introducing a new pre-clinical model of advanced NASH that mimics the main pathophysiological characteristics and transcriptomic signature of the human disease” will be presented by Zoe Boyer-Díaz, Associate Scientist at BLB, and Dr Jordi Gracia-Sancho, CEO and CSO of the company.

In addition to science, BLB is glad to announce its further contribution with the ILC-2019 being part of the Biotech Village. BLB’s working and management teams will be available to meet in the unique BLB’s stand. Look for us to talk about liver research, while having a cup of coffee, in the Biotech Village, stand no. 1!

For more information about the company, current partners and available research services please visit

More News

Barcelona Liver Bioservices (BLB) starts operations

Barcelona Liver Bioservices (BLB), a spin-off of IDIBAPS, has been created for the design and development of pre-clinical studies in the fields of hepatology and hepatotoxicity. The co-founders are Jordi Gracia-Sancho, Jaume Bosch and Joan Carles Garcia-Pagan from IDIBAPS and Rosa Villa from CSIC.

Read More »